Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML (2011) Clin Cancer Res 17: 3794-802 γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000). Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, Jodrell D, Hochhauser D, Hartley JA (2013) Clin Cancer Res 19: 721-30 A novel conjugable translocator protein ligand labeled with a fluorescence dye for in vitro imaging. Bai M, Wyatt SK, Han Z, Papadopoulos V, Bornhop DJ (2007) Bioconjug Chem 18: 1118-22 Cytotoxic and pathogenic properties of Klebsiella oxytoca isolated from laboratory animals. Darby A, Lertpiriyapong K, Sarkar U, Seneviratne U, Park DS, Gamazon ER, Batchelder C, Cheung C, Buckley EM, Taylor NS, Shen Z, Tannenbaum SR, Wishnok JS, Fox JG (2014) PLoS One 9: e100542 Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. Wade Calcutt M, Lee W, Puzanov I, Rothenberg ML, Hachey DL (2008) J Mass Spectrom 43: 42-52
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.